Enicepatide: diabetes-population evidence adds a new chapter
Roche reported Phase 2 results in 447 adults with type 2 diabetes and overweight or obesity.
Development event: September 22, 2026. Written September 23 UTC as reconstructed history, linked to the compound overview.
Roche reported Phase 2 results in 447 adults with type 2 diabetes and overweight or obesity. At 48 weeks, the 24 mg group had a reported HbA1c reduction of 2.65 percentage points and body-weight reduction of 15.5%. These are sponsor-reported changes, not figures described here as placebo-adjusted treatment differences. Gastrointestinal events were common; the release reported adverse-event discontinuation of 2% across enicepatide groups and 0% on placebo. September 22 release.
The result adds diabetes-population evidence to the development history. It cannot be ranked directly against a longer obesity trial excluding diabetes, and it does not settle long-term safety or cardiovascular outcomes. Roche identified additional glycemic and cardiovascular trials as planned for the first half of 2027.
The source connects CT-388-104 with NCT06628362. The registry supplies the study design and identity; the company announcement supplies the newly reported findings. Keeping those roles separate prevents a status update from being misrepresented as a clinical result.
Phase 3 ENITH development and the separate petrelintide combination remain distinct parts of the program. Roche's acquisition and collaboration history explains how this compound entered that broader portfolio. The partnership account (below) preserves the different rights and economics without allocating an entire deal value to these Phase 2 findings.
Roche — company resources
Roche reported CHF 5.448 billion of cash and equivalents and CHF 4.286 billion of other marketable liquidity at June 30, a combined CHF 9.734 billion. Total debt was CHF 31.805 billion; the company's net-debt measure was CHF 22.071 billion. First-half operating cash flow was CHF 7.635 billion and IFRS net income CHF 7.325 billion. The profitable group can fund research from operating businesses, but these figures do not disclose a dedicated budget for either obesity program. Its CHF 4.197 billion free-cash-flow measure is distinct from operating cash flow. Half-year report published July 23.
Roche and Zealand — petrelintide and combination development
The collaboration was announced in March 2025 and became effective in May. Zealand received $1.4 billion upfront in the second quarter of 2025. A further $250 million is scheduled across two anniversaries; the first $125 million was received in the first half of 2026. Potential development and sales milestones total up to $1.2 billion and $2.4 billion respectively and remain contingent.
The partners share profits and losses equally in the United States and Europe, with co-commercialization rights. Roche has exclusive commercialization rights elsewhere, where Zealand is eligible for tiered double-digit royalties reaching the high teens. Roche carries commercial manufacturing investment responsibilities. The program includes petrelintide alone and combinations with Roche's enicepatide; the agreement's aggregate economics should not be assigned wholly to the combination or treated as cash reserved for a single trial. Zealand 2025 annual report, partnership account, 2026 half-year cash receipt.
Roche and Carmot — acquisition and enicepatide
Roche's December 2023 acquisition announcement identified CT-388 among several Carmot clinical programs. The announced consideration included an upfront purchase price and contingent milestones. That portfolio transaction should not be reported as a compound-specific research allocation. Current Roche releases identify CT-388 as enicepatide, while registry records also retain RO7795068. Keeping those names connected prevents an ownership change from appearing to create a new compound. Roche acquisition announcement, Roche development update, September 22, 2026.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment. The development or financing event discussed in this update is dated 2026-09-22. Read the previous compound account.